A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders

Trends in Pharmacological Sciences

Volumn 26, Issue 12, 2005, Pages 609-617

  Witkin, Jeffrey M ^a   Tzavara, Eleni T ^b   Davis, Richard J ^a   Li, Xia ^a   Nomikos, George G ^a  

^a ELI LILLY AND COMPANY   (United States)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABINOID RECEPTOR ANTAGONIST; DESIPRAMINE; DULOXETINE; FLUOXETINE; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

APPETITE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; DRUG DEPENDENCE; HUMAN; MAJOR DEPRESSION; MOOD; NEUROANATOMY; NEUROCHEMISTRY; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 27744529697     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2005.10.006     Document Type: Article

References (77)

1. P. Skolnick Current perspectives on the development of non-biogenic amine-based antidepressants Pharmacol. Res. 43 2001 411 443
2. L. Iversen The monoamine hypothesis of depression J. Licinio M.L. Wong Biology of Depression 2005 Wiley-VCH Winheim 71 86
3. R.S. Duman The neurochemistry of depressive disorders: preclinical studies D.S. Charney E.J. Nestler Neurobiology of Mental Illness 2nd Edn 2004 Oxford University Press 421 439
4. H.K. Manji The cellular neurobiology of depression Nat. Med. 7 2001 541 547
5. A.C. Howlett International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202
6. C.S. Breivogel Evidence for a new G protein-coupled cannabinoid receptor in mouse brain Mol. Pharmacol. 60 2001 155 163
7. N. Hajos Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus Neuroscience 106 2001 1 4
8. K. Monory Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice Biochem. Biophys. Res. Commun. 292 2002 231 235
9. P.M. Zygmunt Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide Nature 400 1999 452 457
10. F. Chaperon, and M.H. Thiebot Behavioral effects of cannabinoid agents in animals Crit. Rev. Neurobiol. 13 1999 243 281
11. N. Hajos Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations Eur. J. Neurosci. 12 2000 3239 3249
12. G. Marsicano The endogenous cannabinoid system controls extinction of aversive memories Nature 418 2002 530 534
13. S.C. Azad Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling J. Neurosci. 24 2004 9953 9961
14. D. Piomelli The endocannabiniod system as a target for therapeutic drugs Trends Pharmacol. Sci. 21 2000 218 224
15. T.F. Freund, and N. Hajos Excitement reduces inhibition via endocannabinoids Neuron 38 2003 362 365
16. R.I. Wilson, and R.A. Nicoll Endocannabinoid signaling in the brain Science 296 2002 678 682
17. E. Schlicker, and M. Kathmann Modulation of transmitter release via presynaptic cannabinoid receptors Trends Pharmacol. Sci. 22 2001 565 572
18. M.A. Diana, and A. Marty Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE) Br. J. Pharmacol. 142 2004 9 19
19. M. Kathmann Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain Naunyn Schmiedebergs Arch. Pharmacol. 359 1999 466 470
20. A.N. Gifford, and C.R. Ashby Jr Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A J. Pharmacol. Exp. Ther. 277 1996 1431 1436
21. N. Auclair Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons J. Neurophysiol. 83 2000 3287 3293
22. E.T. Tzavara The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions Br. J. Pharmacol. 138 2003 544 553
23. S. Mato Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain Eur. J. Pharmacol. 443 2002 43 46
24. M. Steffens Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex Br. J. Pharmacol. 141 2004 1193 1203
25. P. Svenningsson Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac) Proc. Natl. Acad. Sci. U. S. A. 99 2002 3182 3187
26. D. Georgescu The hypothalamic neuropeptide melanin-concentrating hormone act in the nucleus accumbens to modulate feeding behavior and forced-swim performance J. Neurosci. 25 2005 2933 2940
27. J.L. Payne The cellular neurobiology of bipolar disorder D.S. Charney E.J. Nestler Neurobiology of Mental Illness 2nd edn 2004 Oxford University Press 397 420
28. K. Zavitsanou Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 28 2004 355 360
29. B.L. Hungund Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims Mol. Psychiatry 9 2004 184 190
30. K. Vinod Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims Biol. Psychiatry 57 2005 480 486
31. P.W. Zhang Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse Mol. Psychiatry 9 2004 916 931
32. F.J. Barrero Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1) Pharmacogenomics J. 5 2005 135 141
33. C.J. Galynker II Hypofrontality and negative symptoms in major depressive disorder J. Nucl. Med. 39 1998 608 612
34. E. Geuze MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders Mol. Psychiatry 10 2005 160 184
35. S.A. Gruber, and D.A. Yurgelun-Todd Neuroimaging of marijuana smokers during inhibitory processing: a pilot investigation Brain Res. Cogn. Brain Res. 23 2005 107 118
36. M. Rinaldi-Carmona SR141716A, a potent and selective antagonist of the brain cannabinoid receptor FEBS Lett. 350 1994 240 244
37. R.A. Smith, and Z. Fathi Recent advances in the research and development of CB(1) antagonists IDrugs 8 2005 53 66
38. J.R. Fernandez, and D.B. Allison Rimonabant Sanofi-Synthelabo Curr. Opin. Investig. Drugs 5 2004 430 435
39. L.F. Van Gaal Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study Lancet 365 2005 1389 1397
40. O. Jbilo The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance FASEB J. 19 2005 1567 1569
41. E.T. Tzavara The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus Eur. J. Pharmacol. 426 2001 R3 R4
42. G. Tanda Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl.) 115 1994 285 288
43. F.P. Bymaster Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex Psychopharmacology (Berl.) 160 2002 353 361
44. E.T. Tzavara Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action J. Neurosci. 23 2003 9374 9384
45. 2 function Neuroscience 91 1999 607 620
46. S. Patel Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala Neuropsychopharmacology 30 2005 497 507
47. P.J. Zhu, and D.M. Lovinger Retrograde endocannabinoid signaling in a postsynaptic neuron/synaptic bouton preparation from basolateral amygdala J. Neurosci. 25 2005 6199 6207
48. S.J. Gatley 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors Eur. J. Pharmacol. 307 1996 331 338
49. L.P. Shearman Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice Behav. Pharmacol. 14 2003 573 582
50. G. Griebel Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents Biol. Psychiatry 57 2005 261 267
51. I. Barna The role of endogenous cannabinoids in the hypothalamo- pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice Life Sci. 75 2004 2959 2970
52. 1 receptors in mood and anxiety disorders Behav. Pharmacol. 16 2005 315 331
53. V. Santucci Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis Life Sci. 58 1996 PL103 PL110
54. J. Adrien Neurobiological bases for the relationship between sleep and depression Sleep Med. Rev. 6 2002 341 351
55. F.R. Rodriguez de Fonseca Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats Neuroendocrinology 61 1995 714 721
56. F. Rodriguez de Fonseca Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats J. Pharmacol. Exp. Ther. 276 1996 56 64
57. S. Gonzalez Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence Drug Alcohol Depend. 74 2004 159 170
58. S. Kathuria Modulation of anxiety through blockade of anandamide hydrolysis Nat. Med. 9 2003 76 81
59. H.Y. Meltzer Meta-trial study group placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder Am. J. Psychiatry 161 2004 975 984
60. Doraiswamy, P. et al. (2003) Does antidepressant therapy improve cognition in elderly depressed patients? J. Gerontol. A Biol. Sci. Med. Sci. 58, M1137-1144
61. P. Arguello, and J.D. Jentsch Cannabinoid CB1 receptor-mediated impairment of visuospatial attention in the rat Psychopharmacology (Berl.) 177 2004 141 150
62. L. Robinson, and G. Riedel Cannabinoid function in spatial learning: an update Curr. Neuropharm. 2 2004 125 143
63. J.D. Jentsch Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat Neurosci. Lett. 246 1998 169 172
64. C.D. Verrico Repeated, intermittent delta(9)-tetrahydrocannabinol administration to rats impairs acquisition and performance of a test of visuospatial divided attention Neuropsychopharmacology 29 2004 522 529
65. M.C. Wolff, and J.D. Leander SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task Eur. J. Pharmacol. 477 2003 213 217
66. 1 receptor knock-out mice Eur. J. Pharmacol. 379 1999 R1 R2
67. M. Martin Involvement of CB1 cannabinoid receptors in emotional behaviour Psychopharmacology (Berl.) 159 2002 379 387
68. S.A. Varvel, and A.H. Lichtman Evaluation of CB1 receptor knockout mice in the Morris water maze J. Pharmacol. Exp. Ther. 301 2002 915 924
69. J. De Vry Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A Eur. J. Pharmacol. 483 2004 55 63
70. B. Le Foll, and S.R. Goldberg Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence J. Pharmacol. Exp. Ther. 312 2005 875 883
71. 1 receptors control conditioned drug seeking Trends Pharmacol. Sci. 26 2005 420 426
72. S. Paradiso Cognitive impairment in the euthymic phase of chronic unipolar depression J. Nerv. Ment. Dis. 185 1997 748 754
73. L.V. Kessing Cognitive impairment in the euthymic phase of affective disorder Psychol. Med. 28 1998 1027 1038
74. A.K. Jain Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms Obes. Res. 10 2002 1049 1056
75. Need, A.B. et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology (Berl.) (in press)
76. J.F. Cryan Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol. Sci. 23 2002 238 245
77. M.F. O'Neill, and N.A. Moore Animal models of depression: are there any? Hum. Psychopharmacol. 8 2003 239 254